British journal of pharmacology

Br J Pharmacol · ISSN (e) 1476-5381 · 14 papers in corpus
other 2026
doi:10.1111/bph.70360 ·PMID:41707660

BACKGROUND AND PURPOSE: Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is eff…

2022
doi:10.1111/bph.15223 ·PMID:32780479
article 2021
doi:10.1111/bph.15601 ·PMID:34185874

BACKGROUND AND PURPOSE: Limited evidence suggests that the sphingosine-1-phosphate/sphingosine kinase 1 (S1P/SPHK1) signalling pathway is involved in the pathogenesis of endometriosis. Therefore, we analyzed in this study whether the inhibi…

article 2020
doi:10.1111/bph.15044 ·PMID:32144768

BACKGROUND AND PURPOSE: The development of endometriotic lesions is crucially dependent on the formation of new blood vessels. In the present study, we analysed whether this process is regulated by erythropoietin-producing hepatoma receptor…

review 2019
doi:10.1111/bph.14335 ·PMID:29679483

In contrast to the availability of potent and selective antagonists of several prostaglandin receptor types (including DP1 , DP2 , EP and TP receptors), there has been a paucity of well-characterized, selective FP receptor antagonists. The …

article 2018
doi:10.1111/bph.14170 ·PMID:29457968

BACKGROUND AND PURPOSE: A high recurrence rate after medical treatment is a major clinical problem for patients with endometriosis. Here, we have evaluated the in vitro effects of combined treatment with MK2206 (an AKT inhibitor) + chloroqu…

letter 2018
doi:10.1111/bph.14391 ·PMID:29984446

We read with great interest the article by Matsuzaki et al. (2018) entitled ‘In vitro and in vivo effects of MK2206 and chloroquine combination therapy on endometriosis: autophagy may be required for regrowth of endometriosis’ recently publ…

letter 2018
doi:10.1111/bph.14390 ·PMID:29984419

We thank the Editor-in Chief, Professor Amrita Ahluwalia, for her fair handling of the letter from Barra et al. (2018), as well as her openness. We acknowledge the interest of Barra et al. in our work, but we are obliged to respond to their…

article 2017
doi:10.1111/bph.13874 ·PMID:28548231

BACKGROUND AND PURPOSE: Telmisartan suppresses the development of endometriotic lesions. However, the drug also up-regulates the expression of COX-2, which has been suggested to promote the progression of endometriosis. Accordingly, in the …

article 2014
doi:10.1111/bph.12816 ·PMID:24923883

BACKGROUND AND PURPOSE: Lipoxins can function as endogenous 'breaking signals' in inflammation and play important roles in the progression of endometriosis. In this study, we further investigated the molecular mechanism by which lipoxin A4 …

other 2012
doi:10.1111/j.1476-5381.2011.01497.x ·PMID:21595653

BACKGROUND AND PURPOSE: Endometriosis is a disorder in which the endometrium forms growths outside the uterus and is associated with chronic pain. Recent evidence suggests that endometrial motility plays a role in the aetiology of endometri…

article 2011
doi:10.1111/j.1476-5381.2011.01292.x ·PMID:21366552

BACKGROUND AND PURPOSE: 4-Hydroxybenzyl alcohol (HBA) is a phenolic plant compound, which has been shown to influence many cellular mechanisms. In the present study, we analysed in vitro and in vivo the anti-angiogenic actions of this pleio…

review 2006
doi:10.1038/sj.bjp.0706860 ·PMID:16894342

Oral contraceptives, androgenic agents, progestins and gonadotropin-releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted…

article 2006
doi:10.1038/sj.bjp.0706857 ·PMID:16894343

BACKGROUND AND PURPOSE: Rapamycin is a widely used drug with antifungal, immunosuppressant and antiangiogenic effects. Herein, we studied whether immunosuppressive doses of rapamycin are capable of influencing endometriotic lesions. EXPERIM…